[
  {
    "sentence": "Waning vaccine effectiveness in the cancer cohort reached its lowest point at 24–32 weeks following administration of the second vaccine dose (figure 1\n; appendix p 6).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nVaccine effectiveness over time after the second COVID-19 vaccine dose in the cancer cohort versus the control population\nThe error bars represent 95% CIs.To ascertain whether predefined subgroups within the cancer cohort showed greater differences in vaccine effectiveness against breakthrough infections, exploratory analyses were done (table 2\n; figure 2\n; appendix p 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Number of PCR positive and negative test results and vaccine effectiveness in cancer cohort subgroups\n\n\n\n\n\n\n\nOverall vaccine effectiveness\n\nVaccine effectiveness at 3–6 months\n\n\n\n\n\n\n\nExposed (PCR positive)\n\nNot exposed (PCR negative)\n\nVaccine effectiveness (95% CI)\nExposed (PCR positive)\n\nNot exposed (PCR negative)\n\nVaccine effectiveness (95% CI)\n\n\n\n\n\n\nVaccinated (two doses)\nUnvaccinated\nVaccinated (two doses)\nUnvaccinated\n\nVaccinated (two doses)\nUnvaccinated\nVaccinated (two doses)\nUnvaccinated\n\n\n\n\n\nAll patients with cancer\n18 292\n31 649\n780 054\n465 982\n65·5% (65·1–65·9)\n12 513\n31 649\n347 414\n465 982\n47·0% (46·3–47·6)\n\nCancer stage\n\n\nStage 1\n3748\n4678\n139 476\n60 749\n65·1% (64·4–65·8)\n2551\n4678\n64 551\n60 749\n48·7% (47·2–50·1)\n\n\n\nStage 2\n2532\n3387\n104 254\n50 455\n63·8% (62·9–64·8)\n1755\n3387\n46 566\n50 455\n43·9% (42·2–45·5)\n\n\n\nStage 3\n2203\n3649\n109 286\n58 389\n67·7% (66·7–68·8)\n1569\n3649\n48 642\n58 389\n48·4% (46·6–50·1)\n\n\n\nStage 4\n966\n3115\n69 574\n47 760\n78·7% (77·5–79·9)\n674\n3115\n30 209\n47 760\n65·8% (63·7–67·8)\n\n\n\nOther or unknown\n8843\n16 820\n357 464\n248 629\nNA\n5964\n16 820\n157 446\n248 629\nNA\n\nVaccine name or manufacturer (doses 1 and 2)\n\n\nBNT162b2 (Pfizer–BioNtech)\n7050\n31 649\n372 674\n465 982\n72·1% (71·6–72·7)\n4667\n31 649\n167 336\n465 982\n58·9% (58·0–59·9)\n\n\n\nChAdOx1 nCoV-19 (AstraZeneca)\n11 192\n31 649\n402 308\n465 982\n59·0% (58·5–59·6)\n7828\n31 649\n177 512\n465 982\n35·1% (34·1–36·1)\n\n\n\nMixed (Pfizer–BioNtech and AstraZeneca) or other\n50\n0\n5072\n0\nNA\n18\n0\n2566\n0\nNA\n\nCancer diagnosis and treatment\n\n\nTime of diagnosis\n\n\n\n\n≤12 months before data cutoff\n2807\n8286\n162 082\n164 729\n65·6% (64·5–66·6)\n1778\n8286\n63 335\n164 729\n44·2% (42·2–46·1)\n\n\n\n\n>12 months before data cutoff\n15 485\n23 363\n617 972\n301 253\n67·7% (67·3–68·1)\n10 735\n23 363\n284 079\n301 253\n51·3% (50·6–51·9)\n\n\n\nSystemic anticancer therapy\n\n\n\n\nYes\n4633\n9024\n208 369\n158 293\n61·0% (60·1–61·9)\n3328\n9024\n92 068\n158 293\n36·6% (35·1–38·0)\n\n\n\n\nNo\n13 659\n22 625\n571 685\n307 689\n67·5% (67·1–67·9)\n9185\n22 625\n255 346\n307 689\n51·1% (50·4–51·8)\n\n\n\n\nReceived ≤12 months before data cutoff\n3061\n6509\n144 513\n121 632\n60·4% (59·3–61·5)\n2152\n6509\n62 253\n121 632\n35·4% (33·5–37·3)\n\n\n\n\nReceived >12 months before data cutof\n1572\n2515\n63 856\n36 661\n64·1% (62·8–65·4)\n1176\n2515\n29 815\n36 661\n42·5% (40·4–44·6)\n\n\n\nRadiotherapy\n\n\n\n\nYes\n2576\n4591\n114 754\n82 298\n59·8% (58·6–60·9)\n1823\n4591\n51 564\n82 298\n36·6% (34·7–38·5)\n\n\n\n\nNo\n15 716\n27 058\n665 300\n383 684\n66·5% (66·1–66·9)\n10 690\n27 058\n295 850\n383 684\n48·8% (48·1–49·4)\n\n\n\n\nReceived ≤12 months before data cutoff\n911\n2230\n49 023\n50 364\n58·0% (56·0–60·0)\n657\n2230\n21 194\n50 364\n30·0% (26·2–33·7)\n\n\n\n\nReceived >12 months before data cutoff\n1665\n2361\n65 731\n31 934\n65·7% (64·6–66·9)\n1166\n2361\n30 370\n31 934\n48·1% (46·1–50·1)\n\nType of malignancy\n\n\nSolid organ malignancy\n15 070\n26 203\n685 675\n390 844\n67·2% (66·8–67·6)\n10 245\n26 203\n304 288\n390 844\n49·8% (49·1–50·5)\n\n\n\nHaematological malignancy\n3222\n5446\n94 379\n75 138\n52·9% (51·7–54·1)\n2268\n5446\n43 126\n75 138\n27·4% (25·6–29·3)\n\nCancer subtype\n\n\nLip, oral cavity, and pharynx (C00–C14)\n441\n684\n16 718\n13 798\n46·8% (43·5–50·2)\n297\n684\n7353\n13 798\n18·5% (12·9–24·2)\n\n\n\nNon-colorectal gastrointestinal (C15–C17 and C22–C26)\n921\n2698\n61 577\n45 563\n74·7% (73·3–76·2)\n596\n2698\n25 495\n45 563\n60·5% (58·0–62·9)\n\n\n\nColorectal gastrointestinal (C18–C21)\n2031\n3740\n114 874\n63 005\n70·2% (69·2–71·2)\n1399\n3740\n49 974\n63 005\n52·8% (51·1–54·6)\n\n\n\nLung (C34)\n1228\n3344\n70 528\n49 068\n74·5% (73·2–75·7)\n820\n3344\n31 250\n49 068\n61·5% (59·4–63·5)\n\n\n\nRespiratory and intrathoracic organs (C30–C33 and C35–C39)\n161\n359\n7376\n5840\n64·5% (59·9–68·9)\n123\n359\n3304\n5840\n39·4% (32·0–46·6)\n\n\n\nBone, mesothelial, and soft tissue (C40–C41 and C45–C49)\n283\n637\n14 976\n13 091\n61·2% (57·5–64·7)\n185\n637\n6203\n13 091\n38·7% (32·2–44·9)\n\n\n\nBreast (C50)\n3774\n4877\n147 465\n70 606\n62·9% (62·2–63·7)\n2568\n4877\n66 651\n70 606\n44·2% (42·8–45·6)\n\n\n\nFemale gynaecological (C51–C58)\n1095\n2067\n52 094\n33 122\n66·3% (64·7–67·9)\n709\n2067\n23 001\n33 122\n50·6% (48·0–53·2)\n\n\n\nMale urological (C60, C62, and C63)\n234\n428\n5328\n4759\n51·2% (46·5–55·8)\n133\n428\n2294\n4759\n35·5% (28·2–42·6)\n\n\n\nProstate (C61)\n3093\n3867\n108 522\n39 592\n70·8% (70·1–71·5)\n2178\n3867\n50 373\n39 592\n55·7% (54·3–57·2)\n\n\n\nUrinary tract (C64–C68)\n1372\n2223\n70 547\n34 539\n69·8% (68·6–71·0)\n968\n2223\n31 654\n34 539\n52·5% (50·4–54·6)\n\n\n\nCNS (C69–C72)\n186\n789\n8127\n11 991\n65·2% (61·6–69·0)\n117\n789\n3506\n11 991\n49·3% (41·9–56·0)\n\n\n\nEndocrine glands (C73–C75)\n251\n490\n7543\n5870\n60·1% (56·2–64·0)\n152\n490\n3230\n5870\n43·6% (41·9–56·0)\n\n\n\nLymphoma (C81–C85)\n1806\n2427\n37 107\n27 855\n44·1% (42·5–45·8)\n1277\n2427\n16 811\n27 855\n12·8% (10·4–15·3)\n\n\n\nMyeloma (C90)\n472\n918\n29 545\n12 921\n77·5% (75·8–79·2)\n345\n918\n13 458\n12 921\n63·9% (60·7–67·0)\n\n\n\nLeukaemia (C91–C95)\n809\n1954\n24 555\n32 581\n45·1% (42·5–47·6)\n554\n1954\n11 333\n32 581\n18·5% (13·9–23·0)\n\n\n\nOther\n135\n147\n3172\n1781\nNA\n92\n147\n1524\n1781\nNA\n\n\n\nOpen in a new tab\nNA=not applicable.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nHeatmap showing overall vaccine effectiveness after the second dose and the interaction of patient age, sex, and cancer diagnosis\nGrey boxes denote insufficient data; white boxes denote inapplicable sections.Cancer subtype analysis identified that vaccine effectiveness (overall and at 3–6 months) was lower among patients with haematological malignancies than among those with solid organ malignancies, driven principally by those with a diagnosis of lymphoma or leukaemia (table 2; figure 2; appendix p 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "To examine clinically relevant covariates that might drive these differences in the cancer cohort, a multivariable logistic regression model was fitted to adjust for the effects of the age, sex, Index of Multiple Deprivation, and ethnicity (figure 3\n; appendix p 7).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Regression models were fitted for the clinically relevant covariates of age, sex, Index of Multiple Deprivation, and ethnicity.In the adjusted multivariable logistic regression, patients with stage 4 cancers versus all other stages and those aged 70 years or older versus those younger than 70 years had reduced frequencies of breakthrough infections and higher vaccine effectiveness (Figure 2, Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The greatest levels of waning vaccine effectiveness were observed in those with a diagnosis of lymphoma or leukaemia, in those who were diagnosed within 12 months of data cutoff, and in those who had received systemic anticancer treatments or radiotherapy (figure 4\n; appendix p 5).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Waning vaccine effectiveness in the cancer cohort reached its lowest point at 24–32 weeks following administration of the second vaccine dose (figure 1\n; appendix p 6).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nVaccine effectiveness over time after the second COVID-19 vaccine dose in the cancer cohort versus the control population\nThe error bars represent 95% CIs.To ascertain whether predefined subgroups within the cancer cohort showed greater differences in vaccine effectiveness against breakthrough infections, exploratory analyses were done (table 2\n; figure 2\n; appendix p 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Number of PCR positive and negative test results and vaccine effectiveness in cancer cohort subgroups\n\n\n\n\n\n\n\nOverall vaccine effectiveness\n\nVaccine effectiveness at 3–6 months\n\n\n\n\n\n\n\nExposed (PCR positive)\n\nNot exposed (PCR negative)\n\nVaccine effectiveness (95% CI)\nExposed (PCR positive)\n\nNot exposed (PCR negative)\n\nVaccine effectiveness (95% CI)\n\n\n\n\n\n\nVaccinated (two doses)\nUnvaccinated\nVaccinated (two doses)\nUnvaccinated\n\nVaccinated (two doses)\nUnvaccinated\nVaccinated (two doses)\nUnvaccinated\n\n\n\n\n\nAll patients with cancer\n18 292\n31 649\n780 054\n465 982\n65·5% (65·1–65·9)\n12 513\n31 649\n347 414\n465 982\n47·0% (46·3–47·6)\n\nCancer stage\n\n\nStage 1\n3748\n4678\n139 476\n60 749\n65·1% (64·4–65·8)\n2551\n4678\n64 551\n60 749\n48·7% (47·2–50·1)\n\n\n\nStage 2\n2532\n3387\n104 254\n50 455\n63·8% (62·9–64·8)\n1755\n3387\n46 566\n50 455\n43·9% (42·2–45·5)\n\n\n\nStage 3\n2203\n3649\n109 286\n58 389\n67·7% (66·7–68·8)\n1569\n3649\n48 642\n58 389\n48·4% (46·6–50·1)\n\n\n\nStage 4\n966\n3115\n69 574\n47 760\n78·7% (77·5–79·9)\n674\n3115\n30 209\n47 760\n65·8% (63·7–67·8)\n\n\n\nOther or unknown\n8843\n16 820\n357 464\n248 629\nNA\n5964\n16 820\n157 446\n248 629\nNA\n\nVaccine name or manufacturer (doses 1 and 2)\n\n\nBNT162b2 (Pfizer–BioNtech)\n7050\n31 649\n372 674\n465 982\n72·1% (71·6–72·7)\n4667\n31 649\n167 336\n465 982\n58·9% (58·0–59·9)\n\n\n\nChAdOx1 nCoV-19 (AstraZeneca)\n11 192\n31 649\n402 308\n465 982\n59·0% (58·5–59·6)\n7828\n31 649\n177 512\n465 982\n35·1% (34·1–36·1)\n\n\n\nMixed (Pfizer–BioNtech and AstraZeneca) or other\n50\n0\n5072\n0\nNA\n18\n0\n2566\n0\nNA\n\nCancer diagnosis and treatment\n\n\nTime of diagnosis\n\n\n\n\n≤12 months before data cutoff\n2807\n8286\n162 082\n164 729\n65·6% (64·5–66·6)\n1778\n8286\n63 335\n164 729\n44·2% (42·2–46·1)\n\n\n\n\n>12 months before data cutoff\n15 485\n23 363\n617 972\n301 253\n67·7% (67·3–68·1)\n10 735\n23 363\n284 079\n301 253\n51·3% (50·6–51·9)\n\n\n\nSystemic anticancer therapy\n\n\n\n\nYes\n4633\n9024\n208 369\n158 293\n61·0% (60·1–61·9)\n3328\n9024\n92 068\n158 293\n36·6% (35·1–38·0)\n\n\n\n\nNo\n13 659\n22 625\n571 685\n307 689\n67·5% (67·1–67·9)\n9185\n22 625\n255 346\n307 689\n51·1% (50·4–51·8)\n\n\n\n\nReceived ≤12 months before data cutoff\n3061\n6509\n144 513\n121 632\n60·4% (59·3–61·5)\n2152\n6509\n62 253\n121 632\n35·4% (33·5–37·3)\n\n\n\n\nReceived >12 months before data cutof\n1572\n2515\n63 856\n36 661\n64·1% (62·8–65·4)\n1176\n2515\n29 815\n36 661\n42·5% (40·4–44·6)\n\n\n\nRadiotherapy\n\n\n\n\nYes\n2576\n4591\n114 754\n82 298\n59·8% (58·6–60·9)\n1823\n4591\n51 564\n82 298\n36·6% (34·7–38·5)\n\n\n\n\nNo\n15 716\n27 058\n665 300\n383 684\n66·5% (66·1–66·9)\n10 690\n27 058\n295 850\n383 684\n48·8% (48·1–49·4)\n\n\n\n\nReceived ≤12 months before data cutoff\n911\n2230\n49 023\n50 364\n58·0% (56·0–60·0)\n657\n2230\n21 194\n50 364\n30·0% (26·2–33·7)\n\n\n\n\nReceived >12 months before data cutoff\n1665\n2361\n65 731\n31 934\n65·7% (64·6–66·9)\n1166\n2361\n30 370\n31 934\n48·1% (46·1–50·1)\n\nType of malignancy\n\n\nSolid organ malignancy\n15 070\n26 203\n685 675\n390 844\n67·2% (66·8–67·6)\n10 245\n26 203\n304 288\n390 844\n49·8% (49·1–50·5)\n\n\n\nHaematological malignancy\n3222\n5446\n94 379\n75 138\n52·9% (51·7–54·1)\n2268\n5446\n43 126\n75 138\n27·4% (25·6–29·3)\n\nCancer subtype\n\n\nLip, oral cavity, and pharynx (C00–C14)\n441\n684\n16 718\n13 798\n46·8% (43·5–50·2)\n297\n684\n7353\n13 798\n18·5% (12·9–24·2)\n\n\n\nNon-colorectal gastrointestinal (C15–C17 and C22–C26)\n921\n2698\n61 577\n45 563\n74·7% (73·3–76·2)\n596\n2698\n25 495\n45 563\n60·5% (58·0–62·9)\n\n\n\nColorectal gastrointestinal (C18–C21)\n2031\n3740\n114 874\n63 005\n70·2% (69·2–71·2)\n1399\n3740\n49 974\n63 005\n52·8% (51·1–54·6)\n\n\n\nLung (C34)\n1228\n3344\n70 528\n49 068\n74·5% (73·2–75·7)\n820\n3344\n31 250\n49 068\n61·5% (59·4–63·5)\n\n\n\nRespiratory and intrathoracic organs (C30–C33 and C35–C39)\n161\n359\n7376\n5840\n64·5% (59·9–68·9)\n123\n359\n3304\n5840\n39·4% (32·0–46·6)\n\n\n\nBone, mesothelial, and soft tissue (C40–C41 and C45–C49)\n283\n637\n14 976\n13 091\n61·2% (57·5–64·7)\n185\n637\n6203\n13 091\n38·7% (32·2–44·9)\n\n\n\nBreast (C50)\n3774\n4877\n147 465\n70 606\n62·9% (62·2–63·7)\n2568\n4877\n66 651\n70 606\n44·2% (42·8–45·6)\n\n\n\nFemale gynaecological (C51–C58)\n1095\n2067\n52 094\n33 122\n66·3% (64·7–67·9)\n709\n2067\n23 001\n33 122\n50·6% (48·0–53·2)\n\n\n\nMale urological (C60, C62, and C63)\n234\n428\n5328\n4759\n51·2% (46·5–55·8)\n133\n428\n2294\n4759\n35·5% (28·2–42·6)\n\n\n\nProstate (C61)\n3093\n3867\n108 522\n39 592\n70·8% (70·1–71·5)\n2178\n3867\n50 373\n39 592\n55·7% (54·3–57·2)\n\n\n\nUrinary tract (C64–C68)\n1372\n2223\n70 547\n34 539\n69·8% (68·6–71·0)\n968\n2223\n31 654\n34 539\n52·5% (50·4–54·6)\n\n\n\nCNS (C69–C72)\n186\n789\n8127\n11 991\n65·2% (61·6–69·0)\n117\n789\n3506\n11 991\n49·3% (41·9–56·0)\n\n\n\nEndocrine glands (C73–C75)\n251\n490\n7543\n5870\n60·1% (56·2–64·0)\n152\n490\n3230\n5870\n43·6% (41·9–56·0)\n\n\n\nLymphoma (C81–C85)\n1806\n2427\n37 107\n27 855\n44·1% (42·5–45·8)\n1277\n2427\n16 811\n27 855\n12·8% (10·4–15·3)\n\n\n\nMyeloma (C90)\n472\n918\n29 545\n12 921\n77·5% (75·8–79·2)\n345\n918\n13 458\n12 921\n63·9% (60·7–67·0)\n\n\n\nLeukaemia (C91–C95)\n809\n1954\n24 555\n32 581\n45·1% (42·5–47·6)\n554\n1954\n11 333\n32 581\n18·5% (13·9–23·0)\n\n\n\nOther\n135\n147\n3172\n1781\nNA\n92\n147\n1524\n1781\nNA\n\n\n\nOpen in a new tab\nNA=not applicable.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nHeatmap showing overall vaccine effectiveness after the second dose and the interaction of patient age, sex, and cancer diagnosis\nGrey boxes denote insufficient data; white boxes denote inapplicable sections.Cancer subtype analysis identified that vaccine effectiveness (overall and at 3–6 months) was lower among patients with haematological malignancies than among those with solid organ malignancies, driven principally by those with a diagnosis of lymphoma or leukaemia (table 2; figure 2; appendix p 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "To examine clinically relevant covariates that might drive these differences in the cancer cohort, a multivariable logistic regression model was fitted to adjust for the effects of the age, sex, Index of Multiple Deprivation, and ethnicity (figure 3\n; appendix p 7).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Regression models were fitted for the clinically relevant covariates of age, sex, Index of Multiple Deprivation, and ethnicity.In the adjusted multivariable logistic regression, patients with stage 4 cancers versus all other stages and those aged 70 years or older versus those younger than 70 years had reduced frequencies of breakthrough infections and higher vaccine effectiveness (Figure 2, Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The greatest levels of waning vaccine effectiveness were observed in those with a diagnosis of lymphoma or leukaemia, in those who were diagnosed within 12 months of data cutoff, and in those who had received systemic anticancer treatments or radiotherapy (figure 4\n; appendix p 5).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Waning vaccine effectiveness in the cancer cohort reached its lowest point at 24–32 weeks following administration of the second vaccine dose (figure 1\n; appendix p 6).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nVaccine effectiveness over time after the second COVID-19 vaccine dose in the cancer cohort versus the control population\nThe error bars represent 95% CIs.To ascertain whether predefined subgroups within the cancer cohort showed greater differences in vaccine effectiveness against breakthrough infections, exploratory analyses were done (table 2\n; figure 2\n; appendix p 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Number of PCR positive and negative test results and vaccine effectiveness in cancer cohort subgroups\n\n\n\n\n\n\n\nOverall vaccine effectiveness\n\nVaccine effectiveness at 3–6 months\n\n\n\n\n\n\n\nExposed (PCR positive)\n\nNot exposed (PCR negative)\n\nVaccine effectiveness (95% CI)\nExposed (PCR positive)\n\nNot exposed (PCR negative)\n\nVaccine effectiveness (95% CI)\n\n\n\n\n\n\nVaccinated (two doses)\nUnvaccinated\nVaccinated (two doses)\nUnvaccinated\n\nVaccinated (two doses)\nUnvaccinated\nVaccinated (two doses)\nUnvaccinated\n\n\n\n\n\nAll patients with cancer\n18 292\n31 649\n780 054\n465 982\n65·5% (65·1–65·9)\n12 513\n31 649\n347 414\n465 982\n47·0% (46·3–47·6)\n\nCancer stage\n\n\nStage 1\n3748\n4678\n139 476\n60 749\n65·1% (64·4–65·8)\n2551\n4678\n64 551\n60 749\n48·7% (47·2–50·1)\n\n\n\nStage 2\n2532\n3387\n104 254\n50 455\n63·8% (62·9–64·8)\n1755\n3387\n46 566\n50 455\n43·9% (42·2–45·5)\n\n\n\nStage 3\n2203\n3649\n109 286\n58 389\n67·7% (66·7–68·8)\n1569\n3649\n48 642\n58 389\n48·4% (46·6–50·1)\n\n\n\nStage 4\n966\n3115\n69 574\n47 760\n78·7% (77·5–79·9)\n674\n3115\n30 209\n47 760\n65·8% (63·7–67·8)\n\n\n\nOther or unknown\n8843\n16 820\n357 464\n248 629\nNA\n5964\n16 820\n157 446\n248 629\nNA\n\nVaccine name or manufacturer (doses 1 and 2)\n\n\nBNT162b2 (Pfizer–BioNtech)\n7050\n31 649\n372 674\n465 982\n72·1% (71·6–72·7)\n4667\n31 649\n167 336\n465 982\n58·9% (58·0–59·9)\n\n\n\nChAdOx1 nCoV-19 (AstraZeneca)\n11 192\n31 649\n402 308\n465 982\n59·0% (58·5–59·6)\n7828\n31 649\n177 512\n465 982\n35·1% (34·1–36·1)\n\n\n\nMixed (Pfizer–BioNtech and AstraZeneca) or other\n50\n0\n5072\n0\nNA\n18\n0\n2566\n0\nNA\n\nCancer diagnosis and treatment\n\n\nTime of diagnosis\n\n\n\n\n≤12 months before data cutoff\n2807\n8286\n162 082\n164 729\n65·6% (64·5–66·6)\n1778\n8286\n63 335\n164 729\n44·2% (42·2–46·1)\n\n\n\n\n>12 months before data cutoff\n15 485\n23 363\n617 972\n301 253\n67·7% (67·3–68·1)\n10 735\n23 363\n284 079\n301 253\n51·3% (50·6–51·9)\n\n\n\nSystemic anticancer therapy\n\n\n\n\nYes\n4633\n9024\n208 369\n158 293\n61·0% (60·1–61·9)\n3328\n9024\n92 068\n158 293\n36·6% (35·1–38·0)\n\n\n\n\nNo\n13 659\n22 625\n571 685\n307 689\n67·5% (67·1–67·9)\n9185\n22 625\n255 346\n307 689\n51·1% (50·4–51·8)\n\n\n\n\nReceived ≤12 months before data cutoff\n3061\n6509\n144 513\n121 632\n60·4% (59·3–61·5)\n2152\n6509\n62 253\n121 632\n35·4% (33·5–37·3)\n\n\n\n\nReceived >12 months before data cutof\n1572\n2515\n63 856\n36 661\n64·1% (62·8–65·4)\n1176\n2515\n29 815\n36 661\n42·5% (40·4–44·6)\n\n\n\nRadiotherapy\n\n\n\n\nYes\n2576\n4591\n114 754\n82 298\n59·8% (58·6–60·9)\n1823\n4591\n51 564\n82 298\n36·6% (34·7–38·5)\n\n\n\n\nNo\n15 716\n27 058\n665 300\n383 684\n66·5% (66·1–66·9)\n10 690\n27 058\n295 850\n383 684\n48·8% (48·1–49·4)\n\n\n\n\nReceived ≤12 months before data cutoff\n911\n2230\n49 023\n50 364\n58·0% (56·0–60·0)\n657\n2230\n21 194\n50 364\n30·0% (26·2–33·7)\n\n\n\n\nReceived >12 months before data cutoff\n1665\n2361\n65 731\n31 934\n65·7% (64·6–66·9)\n1166\n2361\n30 370\n31 934\n48·1% (46·1–50·1)\n\nType of malignancy\n\n\nSolid organ malignancy\n15 070\n26 203\n685 675\n390 844\n67·2% (66·8–67·6)\n10 245\n26 203\n304 288\n390 844\n49·8% (49·1–50·5)\n\n\n\nHaematological malignancy\n3222\n5446\n94 379\n75 138\n52·9% (51·7–54·1)\n2268\n5446\n43 126\n75 138\n27·4% (25·6–29·3)\n\nCancer subtype\n\n\nLip, oral cavity, and pharynx (C00–C14)\n441\n684\n16 718\n13 798\n46·8% (43·5–50·2)\n297\n684\n7353\n13 798\n18·5% (12·9–24·2)\n\n\n\nNon-colorectal gastrointestinal (C15–C17 and C22–C26)\n921\n2698\n61 577\n45 563\n74·7% (73·3–76·2)\n596\n2698\n25 495\n45 563\n60·5% (58·0–62·9)\n\n\n\nColorectal gastrointestinal (C18–C21)\n2031\n3740\n114 874\n63 005\n70·2% (69·2–71·2)\n1399\n3740\n49 974\n63 005\n52·8% (51·1–54·6)\n\n\n\nLung (C34)\n1228\n3344\n70 528\n49 068\n74·5% (73·2–75·7)\n820\n3344\n31 250\n49 068\n61·5% (59·4–63·5)\n\n\n\nRespiratory and intrathoracic organs (C30–C33 and C35–C39)\n161\n359\n7376\n5840\n64·5% (59·9–68·9)\n123\n359\n3304\n5840\n39·4% (32·0–46·6)\n\n\n\nBone, mesothelial, and soft tissue (C40–C41 and C45–C49)\n283\n637\n14 976\n13 091\n61·2% (57·5–64·7)\n185\n637\n6203\n13 091\n38·7% (32·2–44·9)\n\n\n\nBreast (C50)\n3774\n4877\n147 465\n70 606\n62·9% (62·2–63·7)\n2568\n4877\n66 651\n70 606\n44·2% (42·8–45·6)\n\n\n\nFemale gynaecological (C51–C58)\n1095\n2067\n52 094\n33 122\n66·3% (64·7–67·9)\n709\n2067\n23 001\n33 122\n50·6% (48·0–53·2)\n\n\n\nMale urological (C60, C62, and C63)\n234\n428\n5328\n4759\n51·2% (46·5–55·8)\n133\n428\n2294\n4759\n35·5% (28·2–42·6)\n\n\n\nProstate (C61)\n3093\n3867\n108 522\n39 592\n70·8% (70·1–71·5)\n2178\n3867\n50 373\n39 592\n55·7% (54·3–57·2)\n\n\n\nUrinary tract (C64–C68)\n1372\n2223\n70 547\n34 539\n69·8% (68·6–71·0)\n968\n2223\n31 654\n34 539\n52·5% (50·4–54·6)\n\n\n\nCNS (C69–C72)\n186\n789\n8127\n11 991\n65·2% (61·6–69·0)\n117\n789\n3506\n11 991\n49·3% (41·9–56·0)\n\n\n\nEndocrine glands (C73–C75)\n251\n490\n7543\n5870\n60·1% (56·2–64·0)\n152\n490\n3230\n5870\n43·6% (41·9–56·0)\n\n\n\nLymphoma (C81–C85)\n1806\n2427\n37 107\n27 855\n44·1% (42·5–45·8)\n1277\n2427\n16 811\n27 855\n12·8% (10·4–15·3)\n\n\n\nMyeloma (C90)\n472\n918\n29 545\n12 921\n77·5% (75·8–79·2)\n345\n918\n13 458\n12 921\n63·9% (60·7–67·0)\n\n\n\nLeukaemia (C91–C95)\n809\n1954\n24 555\n32 581\n45·1% (42·5–47·6)\n554\n1954\n11 333\n32 581\n18·5% (13·9–23·0)\n\n\n\nOther\n135\n147\n3172\n1781\nNA\n92\n147\n1524\n1781\nNA\n\n\n\nOpen in a new tab\nNA=not applicable.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nHeatmap showing overall vaccine effectiveness after the second dose and the interaction of patient age, sex, and cancer diagnosis\nGrey boxes denote insufficient data; white boxes denote inapplicable sections.Cancer subtype analysis identified that vaccine effectiveness (overall and at 3–6 months) was lower among patients with haematological malignancies than among those with solid organ malignancies, driven principally by those with a diagnosis of lymphoma or leukaemia (table 2; figure 2; appendix p 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "To examine clinically relevant covariates that might drive these differences in the cancer cohort, a multivariable logistic regression model was fitted to adjust for the effects of the age, sex, Index of Multiple Deprivation, and ethnicity (figure 3\n; appendix p 7).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Regression models were fitted for the clinically relevant covariates of age, sex, Index of Multiple Deprivation, and ethnicity.In the adjusted multivariable logistic regression, patients with stage 4 cancers versus all other stages and those aged 70 years or older versus those younger than 70 years had reduced frequencies of breakthrough infections and higher vaccine effectiveness (Figure 2, Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The greatest levels of waning vaccine effectiveness were observed in those with a diagnosis of lymphoma or leukaemia, in those who were diagnosed within 12 months of data cutoff, and in those who had received systemic anticancer treatments or radiotherapy (figure 4\n; appendix p 5).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Waning vaccine effectiveness in the cancer cohort reached its lowest point at 24–32 weeks following administration of the second vaccine dose (figure 1\n; appendix p 6).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nVaccine effectiveness over time after the second COVID-19 vaccine dose in the cancer cohort versus the control population\nThe error bars represent 95% CIs.To ascertain whether predefined subgroups within the cancer cohort showed greater differences in vaccine effectiveness against breakthrough infections, exploratory analyses were done (table 2\n; figure 2\n; appendix p 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Number of PCR positive and negative test results and vaccine effectiveness in cancer cohort subgroups\n\n\n\n\n\n\n\nOverall vaccine effectiveness\n\nVaccine effectiveness at 3–6 months\n\n\n\n\n\n\n\nExposed (PCR positive)\n\nNot exposed (PCR negative)\n\nVaccine effectiveness (95% CI)\nExposed (PCR positive)\n\nNot exposed (PCR negative)\n\nVaccine effectiveness (95% CI)\n\n\n\n\n\n\nVaccinated (two doses)\nUnvaccinated\nVaccinated (two doses)\nUnvaccinated\n\nVaccinated (two doses)\nUnvaccinated\nVaccinated (two doses)\nUnvaccinated\n\n\n\n\n\nAll patients with cancer\n18 292\n31 649\n780 054\n465 982\n65·5% (65·1–65·9)\n12 513\n31 649\n347 414\n465 982\n47·0% (46·3–47·6)\n\nCancer stage\n\n\nStage 1\n3748\n4678\n139 476\n60 749\n65·1% (64·4–65·8)\n2551\n4678\n64 551\n60 749\n48·7% (47·2–50·1)\n\n\n\nStage 2\n2532\n3387\n104 254\n50 455\n63·8% (62·9–64·8)\n1755\n3387\n46 566\n50 455\n43·9% (42·2–45·5)\n\n\n\nStage 3\n2203\n3649\n109 286\n58 389\n67·7% (66·7–68·8)\n1569\n3649\n48 642\n58 389\n48·4% (46·6–50·1)\n\n\n\nStage 4\n966\n3115\n69 574\n47 760\n78·7% (77·5–79·9)\n674\n3115\n30 209\n47 760\n65·8% (63·7–67·8)\n\n\n\nOther or unknown\n8843\n16 820\n357 464\n248 629\nNA\n5964\n16 820\n157 446\n248 629\nNA\n\nVaccine name or manufacturer (doses 1 and 2)\n\n\nBNT162b2 (Pfizer–BioNtech)\n7050\n31 649\n372 674\n465 982\n72·1% (71·6–72·7)\n4667\n31 649\n167 336\n465 982\n58·9% (58·0–59·9)\n\n\n\nChAdOx1 nCoV-19 (AstraZeneca)\n11 192\n31 649\n402 308\n465 982\n59·0% (58·5–59·6)\n7828\n31 649\n177 512\n465 982\n35·1% (34·1–36·1)\n\n\n\nMixed (Pfizer–BioNtech and AstraZeneca) or other\n50\n0\n5072\n0\nNA\n18\n0\n2566\n0\nNA\n\nCancer diagnosis and treatment\n\n\nTime of diagnosis\n\n\n\n\n≤12 months before data cutoff\n2807\n8286\n162 082\n164 729\n65·6% (64·5–66·6)\n1778\n8286\n63 335\n164 729\n44·2% (42·2–46·1)\n\n\n\n\n>12 months before data cutoff\n15 485\n23 363\n617 972\n301 253\n67·7% (67·3–68·1)\n10 735\n23 363\n284 079\n301 253\n51·3% (50·6–51·9)\n\n\n\nSystemic anticancer therapy\n\n\n\n\nYes\n4633\n9024\n208 369\n158 293\n61·0% (60·1–61·9)\n3328\n9024\n92 068\n158 293\n36·6% (35·1–38·0)\n\n\n\n\nNo\n13 659\n22 625\n571 685\n307 689\n67·5% (67·1–67·9)\n9185\n22 625\n255 346\n307 689\n51·1% (50·4–51·8)\n\n\n\n\nReceived ≤12 months before data cutoff\n3061\n6509\n144 513\n121 632\n60·4% (59·3–61·5)\n2152\n6509\n62 253\n121 632\n35·4% (33·5–37·3)\n\n\n\n\nReceived >12 months before data cutof\n1572\n2515\n63 856\n36 661\n64·1% (62·8–65·4)\n1176\n2515\n29 815\n36 661\n42·5% (40·4–44·6)\n\n\n\nRadiotherapy\n\n\n\n\nYes\n2576\n4591\n114 754\n82 298\n59·8% (58·6–60·9)\n1823\n4591\n51 564\n82 298\n36·6% (34·7–38·5)\n\n\n\n\nNo\n15 716\n27 058\n665 300\n383 684\n66·5% (66·1–66·9)\n10 690\n27 058\n295 850\n383 684\n48·8% (48·1–49·4)\n\n\n\n\nReceived ≤12 months before data cutoff\n911\n2230\n49 023\n50 364\n58·0% (56·0–60·0)\n657\n2230\n21 194\n50 364\n30·0% (26·2–33·7)\n\n\n\n\nReceived >12 months before data cutoff\n1665\n2361\n65 731\n31 934\n65·7% (64·6–66·9)\n1166\n2361\n30 370\n31 934\n48·1% (46·1–50·1)\n\nType of malignancy\n\n\nSolid organ malignancy\n15 070\n26 203\n685 675\n390 844\n67·2% (66·8–67·6)\n10 245\n26 203\n304 288\n390 844\n49·8% (49·1–50·5)\n\n\n\nHaematological malignancy\n3222\n5446\n94 379\n75 138\n52·9% (51·7–54·1)\n2268\n5446\n43 126\n75 138\n27·4% (25·6–29·3)\n\nCancer subtype\n\n\nLip, oral cavity, and pharynx (C00–C14)\n441\n684\n16 718\n13 798\n46·8% (43·5–50·2)\n297\n684\n7353\n13 798\n18·5% (12·9–24·2)\n\n\n\nNon-colorectal gastrointestinal (C15–C17 and C22–C26)\n921\n2698\n61 577\n45 563\n74·7% (73·3–76·2)\n596\n2698\n25 495\n45 563\n60·5% (58·0–62·9)\n\n\n\nColorectal gastrointestinal (C18–C21)\n2031\n3740\n114 874\n63 005\n70·2% (69·2–71·2)\n1399\n3740\n49 974\n63 005\n52·8% (51·1–54·6)\n\n\n\nLung (C34)\n1228\n3344\n70 528\n49 068\n74·5% (73·2–75·7)\n820\n3344\n31 250\n49 068\n61·5% (59·4–63·5)\n\n\n\nRespiratory and intrathoracic organs (C30–C33 and C35–C39)\n161\n359\n7376\n5840\n64·5% (59·9–68·9)\n123\n359\n3304\n5840\n39·4% (32·0–46·6)\n\n\n\nBone, mesothelial, and soft tissue (C40–C41 and C45–C49)\n283\n637\n14 976\n13 091\n61·2% (57·5–64·7)\n185\n637\n6203\n13 091\n38·7% (32·2–44·9)\n\n\n\nBreast (C50)\n3774\n4877\n147 465\n70 606\n62·9% (62·2–63·7)\n2568\n4877\n66 651\n70 606\n44·2% (42·8–45·6)\n\n\n\nFemale gynaecological (C51–C58)\n1095\n2067\n52 094\n33 122\n66·3% (64·7–67·9)\n709\n2067\n23 001\n33 122\n50·6% (48·0–53·2)\n\n\n\nMale urological (C60, C62, and C63)\n234\n428\n5328\n4759\n51·2% (46·5–55·8)\n133\n428\n2294\n4759\n35·5% (28·2–42·6)\n\n\n\nProstate (C61)\n3093\n3867\n108 522\n39 592\n70·8% (70·1–71·5)\n2178\n3867\n50 373\n39 592\n55·7% (54·3–57·2)\n\n\n\nUrinary tract (C64–C68)\n1372\n2223\n70 547\n34 539\n69·8% (68·6–71·0)\n968\n2223\n31 654\n34 539\n52·5% (50·4–54·6)\n\n\n\nCNS (C69–C72)\n186\n789\n8127\n11 991\n65·2% (61·6–69·0)\n117\n789\n3506\n11 991\n49·3% (41·9–56·0)\n\n\n\nEndocrine glands (C73–C75)\n251\n490\n7543\n5870\n60·1% (56·2–64·0)\n152\n490\n3230\n5870\n43·6% (41·9–56·0)\n\n\n\nLymphoma (C81–C85)\n1806\n2427\n37 107\n27 855\n44·1% (42·5–45·8)\n1277\n2427\n16 811\n27 855\n12·8% (10·4–15·3)\n\n\n\nMyeloma (C90)\n472\n918\n29 545\n12 921\n77·5% (75·8–79·2)\n345\n918\n13 458\n12 921\n63·9% (60·7–67·0)\n\n\n\nLeukaemia (C91–C95)\n809\n1954\n24 555\n32 581\n45·1% (42·5–47·6)\n554\n1954\n11 333\n32 581\n18·5% (13·9–23·0)\n\n\n\nOther\n135\n147\n3172\n1781\nNA\n92\n147\n1524\n1781\nNA\n\n\n\nOpen in a new tab\nNA=not applicable.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nHeatmap showing overall vaccine effectiveness after the second dose and the interaction of patient age, sex, and cancer diagnosis\nGrey boxes denote insufficient data; white boxes denote inapplicable sections.Cancer subtype analysis identified that vaccine effectiveness (overall and at 3–6 months) was lower among patients with haematological malignancies than among those with solid organ malignancies, driven principally by those with a diagnosis of lymphoma or leukaemia (table 2; figure 2; appendix p 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "To examine clinically relevant covariates that might drive these differences in the cancer cohort, a multivariable logistic regression model was fitted to adjust for the effects of the age, sex, Index of Multiple Deprivation, and ethnicity (figure 3\n; appendix p 7).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Regression models were fitted for the clinically relevant covariates of age, sex, Index of Multiple Deprivation, and ethnicity.In the adjusted multivariable logistic regression, patients with stage 4 cancers versus all other stages and those aged 70 years or older versus those younger than 70 years had reduced frequencies of breakthrough infections and higher vaccine effectiveness (Figure 2, Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The greatest levels of waning vaccine effectiveness were observed in those with a diagnosis of lymphoma or leukaemia, in those who were diagnosed within 12 months of data cutoff, and in those who had received systemic anticancer treatments or radiotherapy (figure 4\n; appendix p 5).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Waning vaccine effectiveness in the cancer cohort reached its lowest point at 24–32 weeks following administration of the second vaccine dose (figure 1\n; appendix p 6).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nVaccine effectiveness over time after the second COVID-19 vaccine dose in the cancer cohort versus the control population\nThe error bars represent 95% CIs.To ascertain whether predefined subgroups within the cancer cohort showed greater differences in vaccine effectiveness against breakthrough infections, exploratory analyses were done (table 2\n; figure 2\n; appendix p 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Number of PCR positive and negative test results and vaccine effectiveness in cancer cohort subgroups\n\n\n\n\n\n\n\nOverall vaccine effectiveness\n\nVaccine effectiveness at 3–6 months\n\n\n\n\n\n\n\nExposed (PCR positive)\n\nNot exposed (PCR negative)\n\nVaccine effectiveness (95% CI)\nExposed (PCR positive)\n\nNot exposed (PCR negative)\n\nVaccine effectiveness (95% CI)\n\n\n\n\n\n\nVaccinated (two doses)\nUnvaccinated\nVaccinated (two doses)\nUnvaccinated\n\nVaccinated (two doses)\nUnvaccinated\nVaccinated (two doses)\nUnvaccinated\n\n\n\n\n\nAll patients with cancer\n18 292\n31 649\n780 054\n465 982\n65·5% (65·1–65·9)\n12 513\n31 649\n347 414\n465 982\n47·0% (46·3–47·6)\n\nCancer stage\n\n\nStage 1\n3748\n4678\n139 476\n60 749\n65·1% (64·4–65·8)\n2551\n4678\n64 551\n60 749\n48·7% (47·2–50·1)\n\n\n\nStage 2\n2532\n3387\n104 254\n50 455\n63·8% (62·9–64·8)\n1755\n3387\n46 566\n50 455\n43·9% (42·2–45·5)\n\n\n\nStage 3\n2203\n3649\n109 286\n58 389\n67·7% (66·7–68·8)\n1569\n3649\n48 642\n58 389\n48·4% (46·6–50·1)\n\n\n\nStage 4\n966\n3115\n69 574\n47 760\n78·7% (77·5–79·9)\n674\n3115\n30 209\n47 760\n65·8% (63·7–67·8)\n\n\n\nOther or unknown\n8843\n16 820\n357 464\n248 629\nNA\n5964\n16 820\n157 446\n248 629\nNA\n\nVaccine name or manufacturer (doses 1 and 2)\n\n\nBNT162b2 (Pfizer–BioNtech)\n7050\n31 649\n372 674\n465 982\n72·1% (71·6–72·7)\n4667\n31 649\n167 336\n465 982\n58·9% (58·0–59·9)\n\n\n\nChAdOx1 nCoV-19 (AstraZeneca)\n11 192\n31 649\n402 308\n465 982\n59·0% (58·5–59·6)\n7828\n31 649\n177 512\n465 982\n35·1% (34·1–36·1)\n\n\n\nMixed (Pfizer–BioNtech and AstraZeneca) or other\n50\n0\n5072\n0\nNA\n18\n0\n2566\n0\nNA\n\nCancer diagnosis and treatment\n\n\nTime of diagnosis\n\n\n\n\n≤12 months before data cutoff\n2807\n8286\n162 082\n164 729\n65·6% (64·5–66·6)\n1778\n8286\n63 335\n164 729\n44·2% (42·2–46·1)\n\n\n\n\n>12 months before data cutoff\n15 485\n23 363\n617 972\n301 253\n67·7% (67·3–68·1)\n10 735\n23 363\n284 079\n301 253\n51·3% (50·6–51·9)\n\n\n\nSystemic anticancer therapy\n\n\n\n\nYes\n4633\n9024\n208 369\n158 293\n61·0% (60·1–61·9)\n3328\n9024\n92 068\n158 293\n36·6% (35·1–38·0)\n\n\n\n\nNo\n13 659\n22 625\n571 685\n307 689\n67·5% (67·1–67·9)\n9185\n22 625\n255 346\n307 689\n51·1% (50·4–51·8)\n\n\n\n\nReceived ≤12 months before data cutoff\n3061\n6509\n144 513\n121 632\n60·4% (59·3–61·5)\n2152\n6509\n62 253\n121 632\n35·4% (33·5–37·3)\n\n\n\n\nReceived >12 months before data cutof\n1572\n2515\n63 856\n36 661\n64·1% (62·8–65·4)\n1176\n2515\n29 815\n36 661\n42·5% (40·4–44·6)\n\n\n\nRadiotherapy\n\n\n\n\nYes\n2576\n4591\n114 754\n82 298\n59·8% (58·6–60·9)\n1823\n4591\n51 564\n82 298\n36·6% (34·7–38·5)\n\n\n\n\nNo\n15 716\n27 058\n665 300\n383 684\n66·5% (66·1–66·9)\n10 690\n27 058\n295 850\n383 684\n48·8% (48·1–49·4)\n\n\n\n\nReceived ≤12 months before data cutoff\n911\n2230\n49 023\n50 364\n58·0% (56·0–60·0)\n657\n2230\n21 194\n50 364\n30·0% (26·2–33·7)\n\n\n\n\nReceived >12 months before data cutoff\n1665\n2361\n65 731\n31 934\n65·7% (64·6–66·9)\n1166\n2361\n30 370\n31 934\n48·1% (46·1–50·1)\n\nType of malignancy\n\n\nSolid organ malignancy\n15 070\n26 203\n685 675\n390 844\n67·2% (66·8–67·6)\n10 245\n26 203\n304 288\n390 844\n49·8% (49·1–50·5)\n\n\n\nHaematological malignancy\n3222\n5446\n94 379\n75 138\n52·9% (51·7–54·1)\n2268\n5446\n43 126\n75 138\n27·4% (25·6–29·3)\n\nCancer subtype\n\n\nLip, oral cavity, and pharynx (C00–C14)\n441\n684\n16 718\n13 798\n46·8% (43·5–50·2)\n297\n684\n7353\n13 798\n18·5% (12·9–24·2)\n\n\n\nNon-colorectal gastrointestinal (C15–C17 and C22–C26)\n921\n2698\n61 577\n45 563\n74·7% (73·3–76·2)\n596\n2698\n25 495\n45 563\n60·5% (58·0–62·9)\n\n\n\nColorectal gastrointestinal (C18–C21)\n2031\n3740\n114 874\n63 005\n70·2% (69·2–71·2)\n1399\n3740\n49 974\n63 005\n52·8% (51·1–54·6)\n\n\n\nLung (C34)\n1228\n3344\n70 528\n49 068\n74·5% (73·2–75·7)\n820\n3344\n31 250\n49 068\n61·5% (59·4–63·5)\n\n\n\nRespiratory and intrathoracic organs (C30–C33 and C35–C39)\n161\n359\n7376\n5840\n64·5% (59·9–68·9)\n123\n359\n3304\n5840\n39·4% (32·0–46·6)\n\n\n\nBone, mesothelial, and soft tissue (C40–C41 and C45–C49)\n283\n637\n14 976\n13 091\n61·2% (57·5–64·7)\n185\n637\n6203\n13 091\n38·7% (32·2–44·9)\n\n\n\nBreast (C50)\n3774\n4877\n147 465\n70 606\n62·9% (62·2–63·7)\n2568\n4877\n66 651\n70 606\n44·2% (42·8–45·6)\n\n\n\nFemale gynaecological (C51–C58)\n1095\n2067\n52 094\n33 122\n66·3% (64·7–67·9)\n709\n2067\n23 001\n33 122\n50·6% (48·0–53·2)\n\n\n\nMale urological (C60, C62, and C63)\n234\n428\n5328\n4759\n51·2% (46·5–55·8)\n133\n428\n2294\n4759\n35·5% (28·2–42·6)\n\n\n\nProstate (C61)\n3093\n3867\n108 522\n39 592\n70·8% (70·1–71·5)\n2178\n3867\n50 373\n39 592\n55·7% (54·3–57·2)\n\n\n\nUrinary tract (C64–C68)\n1372\n2223\n70 547\n34 539\n69·8% (68·6–71·0)\n968\n2223\n31 654\n34 539\n52·5% (50·4–54·6)\n\n\n\nCNS (C69–C72)\n186\n789\n8127\n11 991\n65·2% (61·6–69·0)\n117\n789\n3506\n11 991\n49·3% (41·9–56·0)\n\n\n\nEndocrine glands (C73–C75)\n251\n490\n7543\n5870\n60·1% (56·2–64·0)\n152\n490\n3230\n5870\n43·6% (41·9–56·0)\n\n\n\nLymphoma (C81–C85)\n1806\n2427\n37 107\n27 855\n44·1% (42·5–45·8)\n1277\n2427\n16 811\n27 855\n12·8% (10·4–15·3)\n\n\n\nMyeloma (C90)\n472\n918\n29 545\n12 921\n77·5% (75·8–79·2)\n345\n918\n13 458\n12 921\n63·9% (60·7–67·0)\n\n\n\nLeukaemia (C91–C95)\n809\n1954\n24 555\n32 581\n45·1% (42·5–47·6)\n554\n1954\n11 333\n32 581\n18·5% (13·9–23·0)\n\n\n\nOther\n135\n147\n3172\n1781\nNA\n92\n147\n1524\n1781\nNA\n\n\n\nOpen in a new tab\nNA=not applicable.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nHeatmap showing overall vaccine effectiveness after the second dose and the interaction of patient age, sex, and cancer diagnosis\nGrey boxes denote insufficient data; white boxes denote inapplicable sections.Cancer subtype analysis identified that vaccine effectiveness (overall and at 3–6 months) was lower among patients with haematological malignancies than among those with solid organ malignancies, driven principally by those with a diagnosis of lymphoma or leukaemia (table 2; figure 2; appendix p 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "To examine clinically relevant covariates that might drive these differences in the cancer cohort, a multivariable logistic regression model was fitted to adjust for the effects of the age, sex, Index of Multiple Deprivation, and ethnicity (figure 3\n; appendix p 7).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Regression models were fitted for the clinically relevant covariates of age, sex, Index of Multiple Deprivation, and ethnicity.In the adjusted multivariable logistic regression, patients with stage 4 cancers versus all other stages and those aged 70 years or older versus those younger than 70 years had reduced frequencies of breakthrough infections and higher vaccine effectiveness (Figure 2, Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The greatest levels of waning vaccine effectiveness were observed in those with a diagnosis of lymphoma or leukaemia, in those who were diagnosed within 12 months of data cutoff, and in those who had received systemic anticancer treatments or radiotherapy (figure 4\n; appendix p 5).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Waning vaccine effectiveness in the cancer cohort reached its lowest point at 24–32 weeks following administration of the second vaccine dose (figure 1\n; appendix p 6).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nVaccine effectiveness over time after the second COVID-19 vaccine dose in the cancer cohort versus the control population\nThe error bars represent 95% CIs.To ascertain whether predefined subgroups within the cancer cohort showed greater differences in vaccine effectiveness against breakthrough infections, exploratory analyses were done (table 2\n; figure 2\n; appendix p 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Number of PCR positive and negative test results and vaccine effectiveness in cancer cohort subgroups\n\n\n\n\n\n\n\nOverall vaccine effectiveness\n\nVaccine effectiveness at 3–6 months\n\n\n\n\n\n\n\nExposed (PCR positive)\n\nNot exposed (PCR negative)\n\nVaccine effectiveness (95% CI)\nExposed (PCR positive)\n\nNot exposed (PCR negative)\n\nVaccine effectiveness (95% CI)\n\n\n\n\n\n\nVaccinated (two doses)\nUnvaccinated\nVaccinated (two doses)\nUnvaccinated\n\nVaccinated (two doses)\nUnvaccinated\nVaccinated (two doses)\nUnvaccinated\n\n\n\n\n\nAll patients with cancer\n18 292\n31 649\n780 054\n465 982\n65·5% (65·1–65·9)\n12 513\n31 649\n347 414\n465 982\n47·0% (46·3–47·6)\n\nCancer stage\n\n\nStage 1\n3748\n4678\n139 476\n60 749\n65·1% (64·4–65·8)\n2551\n4678\n64 551\n60 749\n48·7% (47·2–50·1)\n\n\n\nStage 2\n2532\n3387\n104 254\n50 455\n63·8% (62·9–64·8)\n1755\n3387\n46 566\n50 455\n43·9% (42·2–45·5)\n\n\n\nStage 3\n2203\n3649\n109 286\n58 389\n67·7% (66·7–68·8)\n1569\n3649\n48 642\n58 389\n48·4% (46·6–50·1)\n\n\n\nStage 4\n966\n3115\n69 574\n47 760\n78·7% (77·5–79·9)\n674\n3115\n30 209\n47 760\n65·8% (63·7–67·8)\n\n\n\nOther or unknown\n8843\n16 820\n357 464\n248 629\nNA\n5964\n16 820\n157 446\n248 629\nNA\n\nVaccine name or manufacturer (doses 1 and 2)\n\n\nBNT162b2 (Pfizer–BioNtech)\n7050\n31 649\n372 674\n465 982\n72·1% (71·6–72·7)\n4667\n31 649\n167 336\n465 982\n58·9% (58·0–59·9)\n\n\n\nChAdOx1 nCoV-19 (AstraZeneca)\n11 192\n31 649\n402 308\n465 982\n59·0% (58·5–59·6)\n7828\n31 649\n177 512\n465 982\n35·1% (34·1–36·1)\n\n\n\nMixed (Pfizer–BioNtech and AstraZeneca) or other\n50\n0\n5072\n0\nNA\n18\n0\n2566\n0\nNA\n\nCancer diagnosis and treatment\n\n\nTime of diagnosis\n\n\n\n\n≤12 months before data cutoff\n2807\n8286\n162 082\n164 729\n65·6% (64·5–66·6)\n1778\n8286\n63 335\n164 729\n44·2% (42·2–46·1)\n\n\n\n\n>12 months before data cutoff\n15 485\n23 363\n617 972\n301 253\n67·7% (67·3–68·1)\n10 735\n23 363\n284 079\n301 253\n51·3% (50·6–51·9)\n\n\n\nSystemic anticancer therapy\n\n\n\n\nYes\n4633\n9024\n208 369\n158 293\n61·0% (60·1–61·9)\n3328\n9024\n92 068\n158 293\n36·6% (35·1–38·0)\n\n\n\n\nNo\n13 659\n22 625\n571 685\n307 689\n67·5% (67·1–67·9)\n9185\n22 625\n255 346\n307 689\n51·1% (50·4–51·8)\n\n\n\n\nReceived ≤12 months before data cutoff\n3061\n6509\n144 513\n121 632\n60·4% (59·3–61·5)\n2152\n6509\n62 253\n121 632\n35·4% (33·5–37·3)\n\n\n\n\nReceived >12 months before data cutof\n1572\n2515\n63 856\n36 661\n64·1% (62·8–65·4)\n1176\n2515\n29 815\n36 661\n42·5% (40·4–44·6)\n\n\n\nRadiotherapy\n\n\n\n\nYes\n2576\n4591\n114 754\n82 298\n59·8% (58·6–60·9)\n1823\n4591\n51 564\n82 298\n36·6% (34·7–38·5)\n\n\n\n\nNo\n15 716\n27 058\n665 300\n383 684\n66·5% (66·1–66·9)\n10 690\n27 058\n295 850\n383 684\n48·8% (48·1–49·4)\n\n\n\n\nReceived ≤12 months before data cutoff\n911\n2230\n49 023\n50 364\n58·0% (56·0–60·0)\n657\n2230\n21 194\n50 364\n30·0% (26·2–33·7)\n\n\n\n\nReceived >12 months before data cutoff\n1665\n2361\n65 731\n31 934\n65·7% (64·6–66·9)\n1166\n2361\n30 370\n31 934\n48·1% (46·1–50·1)\n\nType of malignancy\n\n\nSolid organ malignancy\n15 070\n26 203\n685 675\n390 844\n67·2% (66·8–67·6)\n10 245\n26 203\n304 288\n390 844\n49·8% (49·1–50·5)\n\n\n\nHaematological malignancy\n3222\n5446\n94 379\n75 138\n52·9% (51·7–54·1)\n2268\n5446\n43 126\n75 138\n27·4% (25·6–29·3)\n\nCancer subtype\n\n\nLip, oral cavity, and pharynx (C00–C14)\n441\n684\n16 718\n13 798\n46·8% (43·5–50·2)\n297\n684\n7353\n13 798\n18·5% (12·9–24·2)\n\n\n\nNon-colorectal gastrointestinal (C15–C17 and C22–C26)\n921\n2698\n61 577\n45 563\n74·7% (73·3–76·2)\n596\n2698\n25 495\n45 563\n60·5% (58·0–62·9)\n\n\n\nColorectal gastrointestinal (C18–C21)\n2031\n3740\n114 874\n63 005\n70·2% (69·2–71·2)\n1399\n3740\n49 974\n63 005\n52·8% (51·1–54·6)\n\n\n\nLung (C34)\n1228\n3344\n70 528\n49 068\n74·5% (73·2–75·7)\n820\n3344\n31 250\n49 068\n61·5% (59·4–63·5)\n\n\n\nRespiratory and intrathoracic organs (C30–C33 and C35–C39)\n161\n359\n7376\n5840\n64·5% (59·9–68·9)\n123\n359\n3304\n5840\n39·4% (32·0–46·6)\n\n\n\nBone, mesothelial, and soft tissue (C40–C41 and C45–C49)\n283\n637\n14 976\n13 091\n61·2% (57·5–64·7)\n185\n637\n6203\n13 091\n38·7% (32·2–44·9)\n\n\n\nBreast (C50)\n3774\n4877\n147 465\n70 606\n62·9% (62·2–63·7)\n2568\n4877\n66 651\n70 606\n44·2% (42·8–45·6)\n\n\n\nFemale gynaecological (C51–C58)\n1095\n2067\n52 094\n33 122\n66·3% (64·7–67·9)\n709\n2067\n23 001\n33 122\n50·6% (48·0–53·2)\n\n\n\nMale urological (C60, C62, and C63)\n234\n428\n5328\n4759\n51·2% (46·5–55·8)\n133\n428\n2294\n4759\n35·5% (28·2–42·6)\n\n\n\nProstate (C61)\n3093\n3867\n108 522\n39 592\n70·8% (70·1–71·5)\n2178\n3867\n50 373\n39 592\n55·7% (54·3–57·2)\n\n\n\nUrinary tract (C64–C68)\n1372\n2223\n70 547\n34 539\n69·8% (68·6–71·0)\n968\n2223\n31 654\n34 539\n52·5% (50·4–54·6)\n\n\n\nCNS (C69–C72)\n186\n789\n8127\n11 991\n65·2% (61·6–69·0)\n117\n789\n3506\n11 991\n49·3% (41·9–56·0)\n\n\n\nEndocrine glands (C73–C75)\n251\n490\n7543\n5870\n60·1% (56·2–64·0)\n152\n490\n3230\n5870\n43·6% (41·9–56·0)\n\n\n\nLymphoma (C81–C85)\n1806\n2427\n37 107\n27 855\n44·1% (42·5–45·8)\n1277\n2427\n16 811\n27 855\n12·8% (10·4–15·3)\n\n\n\nMyeloma (C90)\n472\n918\n29 545\n12 921\n77·5% (75·8–79·2)\n345\n918\n13 458\n12 921\n63·9% (60·7–67·0)\n\n\n\nLeukaemia (C91–C95)\n809\n1954\n24 555\n32 581\n45·1% (42·5–47·6)\n554\n1954\n11 333\n32 581\n18·5% (13·9–23·0)\n\n\n\nOther\n135\n147\n3172\n1781\nNA\n92\n147\n1524\n1781\nNA\n\n\n\nOpen in a new tab\nNA=not applicable.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nHeatmap showing overall vaccine effectiveness after the second dose and the interaction of patient age, sex, and cancer diagnosis\nGrey boxes denote insufficient data; white boxes denote inapplicable sections.Cancer subtype analysis identified that vaccine effectiveness (overall and at 3–6 months) was lower among patients with haematological malignancies than among those with solid organ malignancies, driven principally by those with a diagnosis of lymphoma or leukaemia (table 2; figure 2; appendix p 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "To examine clinically relevant covariates that might drive these differences in the cancer cohort, a multivariable logistic regression model was fitted to adjust for the effects of the age, sex, Index of Multiple Deprivation, and ethnicity (figure 3\n; appendix p 7).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Regression models were fitted for the clinically relevant covariates of age, sex, Index of Multiple Deprivation, and ethnicity.In the adjusted multivariable logistic regression, patients with stage 4 cancers versus all other stages and those aged 70 years or older versus those younger than 70 years had reduced frequencies of breakthrough infections and higher vaccine effectiveness (Figure 2, Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The greatest levels of waning vaccine effectiveness were observed in those with a diagnosis of lymphoma or leukaemia, in those who were diagnosed within 12 months of data cutoff, and in those who had received systemic anticancer treatments or radiotherapy (figure 4\n; appendix p 5).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Waning vaccine effectiveness in the cancer cohort reached its lowest point at 24–32 weeks following administration of the second vaccine dose (figure 1\n; appendix p 6).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nVaccine effectiveness over time after the second COVID-19 vaccine dose in the cancer cohort versus the control population\nThe error bars represent 95% CIs.To ascertain whether predefined subgroups within the cancer cohort showed greater differences in vaccine effectiveness against breakthrough infections, exploratory analyses were done (table 2\n; figure 2\n; appendix p 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Number of PCR positive and negative test results and vaccine effectiveness in cancer cohort subgroups\n\n\n\n\n\n\n\nOverall vaccine effectiveness\n\nVaccine effectiveness at 3–6 months\n\n\n\n\n\n\n\nExposed (PCR positive)\n\nNot exposed (PCR negative)\n\nVaccine effectiveness (95% CI)\nExposed (PCR positive)\n\nNot exposed (PCR negative)\n\nVaccine effectiveness (95% CI)\n\n\n\n\n\n\nVaccinated (two doses)\nUnvaccinated\nVaccinated (two doses)\nUnvaccinated\n\nVaccinated (two doses)\nUnvaccinated\nVaccinated (two doses)\nUnvaccinated\n\n\n\n\n\nAll patients with cancer\n18 292\n31 649\n780 054\n465 982\n65·5% (65·1–65·9)\n12 513\n31 649\n347 414\n465 982\n47·0% (46·3–47·6)\n\nCancer stage\n\n\nStage 1\n3748\n4678\n139 476\n60 749\n65·1% (64·4–65·8)\n2551\n4678\n64 551\n60 749\n48·7% (47·2–50·1)\n\n\n\nStage 2\n2532\n3387\n104 254\n50 455\n63·8% (62·9–64·8)\n1755\n3387\n46 566\n50 455\n43·9% (42·2–45·5)\n\n\n\nStage 3\n2203\n3649\n109 286\n58 389\n67·7% (66·7–68·8)\n1569\n3649\n48 642\n58 389\n48·4% (46·6–50·1)\n\n\n\nStage 4\n966\n3115\n69 574\n47 760\n78·7% (77·5–79·9)\n674\n3115\n30 209\n47 760\n65·8% (63·7–67·8)\n\n\n\nOther or unknown\n8843\n16 820\n357 464\n248 629\nNA\n5964\n16 820\n157 446\n248 629\nNA\n\nVaccine name or manufacturer (doses 1 and 2)\n\n\nBNT162b2 (Pfizer–BioNtech)\n7050\n31 649\n372 674\n465 982\n72·1% (71·6–72·7)\n4667\n31 649\n167 336\n465 982\n58·9% (58·0–59·9)\n\n\n\nChAdOx1 nCoV-19 (AstraZeneca)\n11 192\n31 649\n402 308\n465 982\n59·0% (58·5–59·6)\n7828\n31 649\n177 512\n465 982\n35·1% (34·1–36·1)\n\n\n\nMixed (Pfizer–BioNtech and AstraZeneca) or other\n50\n0\n5072\n0\nNA\n18\n0\n2566\n0\nNA\n\nCancer diagnosis and treatment\n\n\nTime of diagnosis\n\n\n\n\n≤12 months before data cutoff\n2807\n8286\n162 082\n164 729\n65·6% (64·5–66·6)\n1778\n8286\n63 335\n164 729\n44·2% (42·2–46·1)\n\n\n\n\n>12 months before data cutoff\n15 485\n23 363\n617 972\n301 253\n67·7% (67·3–68·1)\n10 735\n23 363\n284 079\n301 253\n51·3% (50·6–51·9)\n\n\n\nSystemic anticancer therapy\n\n\n\n\nYes\n4633\n9024\n208 369\n158 293\n61·0% (60·1–61·9)\n3328\n9024\n92 068\n158 293\n36·6% (35·1–38·0)\n\n\n\n\nNo\n13 659\n22 625\n571 685\n307 689\n67·5% (67·1–67·9)\n9185\n22 625\n255 346\n307 689\n51·1% (50·4–51·8)\n\n\n\n\nReceived ≤12 months before data cutoff\n3061\n6509\n144 513\n121 632\n60·4% (59·3–61·5)\n2152\n6509\n62 253\n121 632\n35·4% (33·5–37·3)\n\n\n\n\nReceived >12 months before data cutof\n1572\n2515\n63 856\n36 661\n64·1% (62·8–65·4)\n1176\n2515\n29 815\n36 661\n42·5% (40·4–44·6)\n\n\n\nRadiotherapy\n\n\n\n\nYes\n2576\n4591\n114 754\n82 298\n59·8% (58·6–60·9)\n1823\n4591\n51 564\n82 298\n36·6% (34·7–38·5)\n\n\n\n\nNo\n15 716\n27 058\n665 300\n383 684\n66·5% (66·1–66·9)\n10 690\n27 058\n295 850\n383 684\n48·8% (48·1–49·4)\n\n\n\n\nReceived ≤12 months before data cutoff\n911\n2230\n49 023\n50 364\n58·0% (56·0–60·0)\n657\n2230\n21 194\n50 364\n30·0% (26·2–33·7)\n\n\n\n\nReceived >12 months before data cutoff\n1665\n2361\n65 731\n31 934\n65·7% (64·6–66·9)\n1166\n2361\n30 370\n31 934\n48·1% (46·1–50·1)\n\nType of malignancy\n\n\nSolid organ malignancy\n15 070\n26 203\n685 675\n390 844\n67·2% (66·8–67·6)\n10 245\n26 203\n304 288\n390 844\n49·8% (49·1–50·5)\n\n\n\nHaematological malignancy\n3222\n5446\n94 379\n75 138\n52·9% (51·7–54·1)\n2268\n5446\n43 126\n75 138\n27·4% (25·6–29·3)\n\nCancer subtype\n\n\nLip, oral cavity, and pharynx (C00–C14)\n441\n684\n16 718\n13 798\n46·8% (43·5–50·2)\n297\n684\n7353\n13 798\n18·5% (12·9–24·2)\n\n\n\nNon-colorectal gastrointestinal (C15–C17 and C22–C26)\n921\n2698\n61 577\n45 563\n74·7% (73·3–76·2)\n596\n2698\n25 495\n45 563\n60·5% (58·0–62·9)\n\n\n\nColorectal gastrointestinal (C18–C21)\n2031\n3740\n114 874\n63 005\n70·2% (69·2–71·2)\n1399\n3740\n49 974\n63 005\n52·8% (51·1–54·6)\n\n\n\nLung (C34)\n1228\n3344\n70 528\n49 068\n74·5% (73·2–75·7)\n820\n3344\n31 250\n49 068\n61·5% (59·4–63·5)\n\n\n\nRespiratory and intrathoracic organs (C30–C33 and C35–C39)\n161\n359\n7376\n5840\n64·5% (59·9–68·9)\n123\n359\n3304\n5840\n39·4% (32·0–46·6)\n\n\n\nBone, mesothelial, and soft tissue (C40–C41 and C45–C49)\n283\n637\n14 976\n13 091\n61·2% (57·5–64·7)\n185\n637\n6203\n13 091\n38·7% (32·2–44·9)\n\n\n\nBreast (C50)\n3774\n4877\n147 465\n70 606\n62·9% (62·2–63·7)\n2568\n4877\n66 651\n70 606\n44·2% (42·8–45·6)\n\n\n\nFemale gynaecological (C51–C58)\n1095\n2067\n52 094\n33 122\n66·3% (64·7–67·9)\n709\n2067\n23 001\n33 122\n50·6% (48·0–53·2)\n\n\n\nMale urological (C60, C62, and C63)\n234\n428\n5328\n4759\n51·2% (46·5–55·8)\n133\n428\n2294\n4759\n35·5% (28·2–42·6)\n\n\n\nProstate (C61)\n3093\n3867\n108 522\n39 592\n70·8% (70·1–71·5)\n2178\n3867\n50 373\n39 592\n55·7% (54·3–57·2)\n\n\n\nUrinary tract (C64–C68)\n1372\n2223\n70 547\n34 539\n69·8% (68·6–71·0)\n968\n2223\n31 654\n34 539\n52·5% (50·4–54·6)\n\n\n\nCNS (C69–C72)\n186\n789\n8127\n11 991\n65·2% (61·6–69·0)\n117\n789\n3506\n11 991\n49·3% (41·9–56·0)\n\n\n\nEndocrine glands (C73–C75)\n251\n490\n7543\n5870\n60·1% (56·2–64·0)\n152\n490\n3230\n5870\n43·6% (41·9–56·0)\n\n\n\nLymphoma (C81–C85)\n1806\n2427\n37 107\n27 855\n44·1% (42·5–45·8)\n1277\n2427\n16 811\n27 855\n12·8% (10·4–15·3)\n\n\n\nMyeloma (C90)\n472\n918\n29 545\n12 921\n77·5% (75·8–79·2)\n345\n918\n13 458\n12 921\n63·9% (60·7–67·0)\n\n\n\nLeukaemia (C91–C95)\n809\n1954\n24 555\n32 581\n45·1% (42·5–47·6)\n554\n1954\n11 333\n32 581\n18·5% (13·9–23·0)\n\n\n\nOther\n135\n147\n3172\n1781\nNA\n92\n147\n1524\n1781\nNA\n\n\n\nOpen in a new tab\nNA=not applicable.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nHeatmap showing overall vaccine effectiveness after the second dose and the interaction of patient age, sex, and cancer diagnosis\nGrey boxes denote insufficient data; white boxes denote inapplicable sections.Cancer subtype analysis identified that vaccine effectiveness (overall and at 3–6 months) was lower among patients with haematological malignancies than among those with solid organ malignancies, driven principally by those with a diagnosis of lymphoma or leukaemia (table 2; figure 2; appendix p 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "To examine clinically relevant covariates that might drive these differences in the cancer cohort, a multivariable logistic regression model was fitted to adjust for the effects of the age, sex, Index of Multiple Deprivation, and ethnicity (figure 3\n; appendix p 7).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Regression models were fitted for the clinically relevant covariates of age, sex, Index of Multiple Deprivation, and ethnicity.In the adjusted multivariable logistic regression, patients with stage 4 cancers versus all other stages and those aged 70 years or older versus those younger than 70 years had reduced frequencies of breakthrough infections and higher vaccine effectiveness (Figure 2, Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The greatest levels of waning vaccine effectiveness were observed in those with a diagnosis of lymphoma or leukaemia, in those who were diagnosed within 12 months of data cutoff, and in those who had received systemic anticancer treatments or radiotherapy (figure 4\n; appendix p 5).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Waning vaccine effectiveness in the cancer cohort reached its lowest point at 24–32 weeks following administration of the second vaccine dose (figure 1\n; appendix p 6).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nVaccine effectiveness over time after the second COVID-19 vaccine dose in the cancer cohort versus the control population\nThe error bars represent 95% CIs.To ascertain whether predefined subgroups within the cancer cohort showed greater differences in vaccine effectiveness against breakthrough infections, exploratory analyses were done (table 2\n; figure 2\n; appendix p 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Number of PCR positive and negative test results and vaccine effectiveness in cancer cohort subgroups\n\n\n\n\n\n\n\nOverall vaccine effectiveness\n\nVaccine effectiveness at 3–6 months\n\n\n\n\n\n\n\nExposed (PCR positive)\n\nNot exposed (PCR negative)\n\nVaccine effectiveness (95% CI)\nExposed (PCR positive)\n\nNot exposed (PCR negative)\n\nVaccine effectiveness (95% CI)\n\n\n\n\n\n\nVaccinated (two doses)\nUnvaccinated\nVaccinated (two doses)\nUnvaccinated\n\nVaccinated (two doses)\nUnvaccinated\nVaccinated (two doses)\nUnvaccinated\n\n\n\n\n\nAll patients with cancer\n18 292\n31 649\n780 054\n465 982\n65·5% (65·1–65·9)\n12 513\n31 649\n347 414\n465 982\n47·0% (46·3–47·6)\n\nCancer stage\n\n\nStage 1\n3748\n4678\n139 476\n60 749\n65·1% (64·4–65·8)\n2551\n4678\n64 551\n60 749\n48·7% (47·2–50·1)\n\n\n\nStage 2\n2532\n3387\n104 254\n50 455\n63·8% (62·9–64·8)\n1755\n3387\n46 566\n50 455\n43·9% (42·2–45·5)\n\n\n\nStage 3\n2203\n3649\n109 286\n58 389\n67·7% (66·7–68·8)\n1569\n3649\n48 642\n58 389\n48·4% (46·6–50·1)\n\n\n\nStage 4\n966\n3115\n69 574\n47 760\n78·7% (77·5–79·9)\n674\n3115\n30 209\n47 760\n65·8% (63·7–67·8)\n\n\n\nOther or unknown\n8843\n16 820\n357 464\n248 629\nNA\n5964\n16 820\n157 446\n248 629\nNA\n\nVaccine name or manufacturer (doses 1 and 2)\n\n\nBNT162b2 (Pfizer–BioNtech)\n7050\n31 649\n372 674\n465 982\n72·1% (71·6–72·7)\n4667\n31 649\n167 336\n465 982\n58·9% (58·0–59·9)\n\n\n\nChAdOx1 nCoV-19 (AstraZeneca)\n11 192\n31 649\n402 308\n465 982\n59·0% (58·5–59·6)\n7828\n31 649\n177 512\n465 982\n35·1% (34·1–36·1)\n\n\n\nMixed (Pfizer–BioNtech and AstraZeneca) or other\n50\n0\n5072\n0\nNA\n18\n0\n2566\n0\nNA\n\nCancer diagnosis and treatment\n\n\nTime of diagnosis\n\n\n\n\n≤12 months before data cutoff\n2807\n8286\n162 082\n164 729\n65·6% (64·5–66·6)\n1778\n8286\n63 335\n164 729\n44·2% (42·2–46·1)\n\n\n\n\n>12 months before data cutoff\n15 485\n23 363\n617 972\n301 253\n67·7% (67·3–68·1)\n10 735\n23 363\n284 079\n301 253\n51·3% (50·6–51·9)\n\n\n\nSystemic anticancer therapy\n\n\n\n\nYes\n4633\n9024\n208 369\n158 293\n61·0% (60·1–61·9)\n3328\n9024\n92 068\n158 293\n36·6% (35·1–38·0)\n\n\n\n\nNo\n13 659\n22 625\n571 685\n307 689\n67·5% (67·1–67·9)\n9185\n22 625\n255 346\n307 689\n51·1% (50·4–51·8)\n\n\n\n\nReceived ≤12 months before data cutoff\n3061\n6509\n144 513\n121 632\n60·4% (59·3–61·5)\n2152\n6509\n62 253\n121 632\n35·4% (33·5–37·3)\n\n\n\n\nReceived >12 months before data cutof\n1572\n2515\n63 856\n36 661\n64·1% (62·8–65·4)\n1176\n2515\n29 815\n36 661\n42·5% (40·4–44·6)\n\n\n\nRadiotherapy\n\n\n\n\nYes\n2576\n4591\n114 754\n82 298\n59·8% (58·6–60·9)\n1823\n4591\n51 564\n82 298\n36·6% (34·7–38·5)\n\n\n\n\nNo\n15 716\n27 058\n665 300\n383 684\n66·5% (66·1–66·9)\n10 690\n27 058\n295 850\n383 684\n48·8% (48·1–49·4)\n\n\n\n\nReceived ≤12 months before data cutoff\n911\n2230\n49 023\n50 364\n58·0% (56·0–60·0)\n657\n2230\n21 194\n50 364\n30·0% (26·2–33·7)\n\n\n\n\nReceived >12 months before data cutoff\n1665\n2361\n65 731\n31 934\n65·7% (64·6–66·9)\n1166\n2361\n30 370\n31 934\n48·1% (46·1–50·1)\n\nType of malignancy\n\n\nSolid organ malignancy\n15 070\n26 203\n685 675\n390 844\n67·2% (66·8–67·6)\n10 245\n26 203\n304 288\n390 844\n49·8% (49·1–50·5)\n\n\n\nHaematological malignancy\n3222\n5446\n94 379\n75 138\n52·9% (51·7–54·1)\n2268\n5446\n43 126\n75 138\n27·4% (25·6–29·3)\n\nCancer subtype\n\n\nLip, oral cavity, and pharynx (C00–C14)\n441\n684\n16 718\n13 798\n46·8% (43·5–50·2)\n297\n684\n7353\n13 798\n18·5% (12·9–24·2)\n\n\n\nNon-colorectal gastrointestinal (C15–C17 and C22–C26)\n921\n2698\n61 577\n45 563\n74·7% (73·3–76·2)\n596\n2698\n25 495\n45 563\n60·5% (58·0–62·9)\n\n\n\nColorectal gastrointestinal (C18–C21)\n2031\n3740\n114 874\n63 005\n70·2% (69·2–71·2)\n1399\n3740\n49 974\n63 005\n52·8% (51·1–54·6)\n\n\n\nLung (C34)\n1228\n3344\n70 528\n49 068\n74·5% (73·2–75·7)\n820\n3344\n31 250\n49 068\n61·5% (59·4–63·5)\n\n\n\nRespiratory and intrathoracic organs (C30–C33 and C35–C39)\n161\n359\n7376\n5840\n64·5% (59·9–68·9)\n123\n359\n3304\n5840\n39·4% (32·0–46·6)\n\n\n\nBone, mesothelial, and soft tissue (C40–C41 and C45–C49)\n283\n637\n14 976\n13 091\n61·2% (57·5–64·7)\n185\n637\n6203\n13 091\n38·7% (32·2–44·9)\n\n\n\nBreast (C50)\n3774\n4877\n147 465\n70 606\n62·9% (62·2–63·7)\n2568\n4877\n66 651\n70 606\n44·2% (42·8–45·6)\n\n\n\nFemale gynaecological (C51–C58)\n1095\n2067\n52 094\n33 122\n66·3% (64·7–67·9)\n709\n2067\n23 001\n33 122\n50·6% (48·0–53·2)\n\n\n\nMale urological (C60, C62, and C63)\n234\n428\n5328\n4759\n51·2% (46·5–55·8)\n133\n428\n2294\n4759\n35·5% (28·2–42·6)\n\n\n\nProstate (C61)\n3093\n3867\n108 522\n39 592\n70·8% (70·1–71·5)\n2178\n3867\n50 373\n39 592\n55·7% (54·3–57·2)\n\n\n\nUrinary tract (C64–C68)\n1372\n2223\n70 547\n34 539\n69·8% (68·6–71·0)\n968\n2223\n31 654\n34 539\n52·5% (50·4–54·6)\n\n\n\nCNS (C69–C72)\n186\n789\n8127\n11 991\n65·2% (61·6–69·0)\n117\n789\n3506\n11 991\n49·3% (41·9–56·0)\n\n\n\nEndocrine glands (C73–C75)\n251\n490\n7543\n5870\n60·1% (56·2–64·0)\n152\n490\n3230\n5870\n43·6% (41·9–56·0)\n\n\n\nLymphoma (C81–C85)\n1806\n2427\n37 107\n27 855\n44·1% (42·5–45·8)\n1277\n2427\n16 811\n27 855\n12·8% (10·4–15·3)\n\n\n\nMyeloma (C90)\n472\n918\n29 545\n12 921\n77·5% (75·8–79·2)\n345\n918\n13 458\n12 921\n63·9% (60·7–67·0)\n\n\n\nLeukaemia (C91–C95)\n809\n1954\n24 555\n32 581\n45·1% (42·5–47·6)\n554\n1954\n11 333\n32 581\n18·5% (13·9–23·0)\n\n\n\nOther\n135\n147\n3172\n1781\nNA\n92\n147\n1524\n1781\nNA\n\n\n\nOpen in a new tab\nNA=not applicable.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nHeatmap showing overall vaccine effectiveness after the second dose and the interaction of patient age, sex, and cancer diagnosis\nGrey boxes denote insufficient data; white boxes denote inapplicable sections.Cancer subtype analysis identified that vaccine effectiveness (overall and at 3–6 months) was lower among patients with haematological malignancies than among those with solid organ malignancies, driven principally by those with a diagnosis of lymphoma or leukaemia (table 2; figure 2; appendix p 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "To examine clinically relevant covariates that might drive these differences in the cancer cohort, a multivariable logistic regression model was fitted to adjust for the effects of the age, sex, Index of Multiple Deprivation, and ethnicity (figure 3\n; appendix p 7).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Regression models were fitted for the clinically relevant covariates of age, sex, Index of Multiple Deprivation, and ethnicity.In the adjusted multivariable logistic regression, patients with stage 4 cancers versus all other stages and those aged 70 years or older versus those younger than 70 years had reduced frequencies of breakthrough infections and higher vaccine effectiveness (Figure 2, Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The greatest levels of waning vaccine effectiveness were observed in those with a diagnosis of lymphoma or leukaemia, in those who were diagnosed within 12 months of data cutoff, and in those who had received systemic anticancer treatments or radiotherapy (figure 4\n; appendix p 5).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Waning vaccine effectiveness in the cancer cohort reached its lowest point at 24–32 weeks following administration of the second vaccine dose (figure 1\n; appendix p 6).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nVaccine effectiveness over time after the second COVID-19 vaccine dose in the cancer cohort versus the control population\nThe error bars represent 95% CIs.To ascertain whether predefined subgroups within the cancer cohort showed greater differences in vaccine effectiveness against breakthrough infections, exploratory analyses were done (table 2\n; figure 2\n; appendix p 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Number of PCR positive and negative test results and vaccine effectiveness in cancer cohort subgroups\n\n\n\n\n\n\n\nOverall vaccine effectiveness\n\nVaccine effectiveness at 3–6 months\n\n\n\n\n\n\n\nExposed (PCR positive)\n\nNot exposed (PCR negative)\n\nVaccine effectiveness (95% CI)\nExposed (PCR positive)\n\nNot exposed (PCR negative)\n\nVaccine effectiveness (95% CI)\n\n\n\n\n\n\nVaccinated (two doses)\nUnvaccinated\nVaccinated (two doses)\nUnvaccinated\n\nVaccinated (two doses)\nUnvaccinated\nVaccinated (two doses)\nUnvaccinated\n\n\n\n\n\nAll patients with cancer\n18 292\n31 649\n780 054\n465 982\n65·5% (65·1–65·9)\n12 513\n31 649\n347 414\n465 982\n47·0% (46·3–47·6)\n\nCancer stage\n\n\nStage 1\n3748\n4678\n139 476\n60 749\n65·1% (64·4–65·8)\n2551\n4678\n64 551\n60 749\n48·7% (47·2–50·1)\n\n\n\nStage 2\n2532\n3387\n104 254\n50 455\n63·8% (62·9–64·8)\n1755\n3387\n46 566\n50 455\n43·9% (42·2–45·5)\n\n\n\nStage 3\n2203\n3649\n109 286\n58 389\n67·7% (66·7–68·8)\n1569\n3649\n48 642\n58 389\n48·4% (46·6–50·1)\n\n\n\nStage 4\n966\n3115\n69 574\n47 760\n78·7% (77·5–79·9)\n674\n3115\n30 209\n47 760\n65·8% (63·7–67·8)\n\n\n\nOther or unknown\n8843\n16 820\n357 464\n248 629\nNA\n5964\n16 820\n157 446\n248 629\nNA\n\nVaccine name or manufacturer (doses 1 and 2)\n\n\nBNT162b2 (Pfizer–BioNtech)\n7050\n31 649\n372 674\n465 982\n72·1% (71·6–72·7)\n4667\n31 649\n167 336\n465 982\n58·9% (58·0–59·9)\n\n\n\nChAdOx1 nCoV-19 (AstraZeneca)\n11 192\n31 649\n402 308\n465 982\n59·0% (58·5–59·6)\n7828\n31 649\n177 512\n465 982\n35·1% (34·1–36·1)\n\n\n\nMixed (Pfizer–BioNtech and AstraZeneca) or other\n50\n0\n5072\n0\nNA\n18\n0\n2566\n0\nNA\n\nCancer diagnosis and treatment\n\n\nTime of diagnosis\n\n\n\n\n≤12 months before data cutoff\n2807\n8286\n162 082\n164 729\n65·6% (64·5–66·6)\n1778\n8286\n63 335\n164 729\n44·2% (42·2–46·1)\n\n\n\n\n>12 months before data cutoff\n15 485\n23 363\n617 972\n301 253\n67·7% (67·3–68·1)\n10 735\n23 363\n284 079\n301 253\n51·3% (50·6–51·9)\n\n\n\nSystemic anticancer therapy\n\n\n\n\nYes\n4633\n9024\n208 369\n158 293\n61·0% (60·1–61·9)\n3328\n9024\n92 068\n158 293\n36·6% (35·1–38·0)\n\n\n\n\nNo\n13 659\n22 625\n571 685\n307 689\n67·5% (67·1–67·9)\n9185\n22 625\n255 346\n307 689\n51·1% (50·4–51·8)\n\n\n\n\nReceived ≤12 months before data cutoff\n3061\n6509\n144 513\n121 632\n60·4% (59·3–61·5)\n2152\n6509\n62 253\n121 632\n35·4% (33·5–37·3)\n\n\n\n\nReceived >12 months before data cutof\n1572\n2515\n63 856\n36 661\n64·1% (62·8–65·4)\n1176\n2515\n29 815\n36 661\n42·5% (40·4–44·6)\n\n\n\nRadiotherapy\n\n\n\n\nYes\n2576\n4591\n114 754\n82 298\n59·8% (58·6–60·9)\n1823\n4591\n51 564\n82 298\n36·6% (34·7–38·5)\n\n\n\n\nNo\n15 716\n27 058\n665 300\n383 684\n66·5% (66·1–66·9)\n10 690\n27 058\n295 850\n383 684\n48·8% (48·1–49·4)\n\n\n\n\nReceived ≤12 months before data cutoff\n911\n2230\n49 023\n50 364\n58·0% (56·0–60·0)\n657\n2230\n21 194\n50 364\n30·0% (26·2–33·7)\n\n\n\n\nReceived >12 months before data cutoff\n1665\n2361\n65 731\n31 934\n65·7% (64·6–66·9)\n1166\n2361\n30 370\n31 934\n48·1% (46·1–50·1)\n\nType of malignancy\n\n\nSolid organ malignancy\n15 070\n26 203\n685 675\n390 844\n67·2% (66·8–67·6)\n10 245\n26 203\n304 288\n390 844\n49·8% (49·1–50·5)\n\n\n\nHaematological malignancy\n3222\n5446\n94 379\n75 138\n52·9% (51·7–54·1)\n2268\n5446\n43 126\n75 138\n27·4% (25·6–29·3)\n\nCancer subtype\n\n\nLip, oral cavity, and pharynx (C00–C14)\n441\n684\n16 718\n13 798\n46·8% (43·5–50·2)\n297\n684\n7353\n13 798\n18·5% (12·9–24·2)\n\n\n\nNon-colorectal gastrointestinal (C15–C17 and C22–C26)\n921\n2698\n61 577\n45 563\n74·7% (73·3–76·2)\n596\n2698\n25 495\n45 563\n60·5% (58·0–62·9)\n\n\n\nColorectal gastrointestinal (C18–C21)\n2031\n3740\n114 874\n63 005\n70·2% (69·2–71·2)\n1399\n3740\n49 974\n63 005\n52·8% (51·1–54·6)\n\n\n\nLung (C34)\n1228\n3344\n70 528\n49 068\n74·5% (73·2–75·7)\n820\n3344\n31 250\n49 068\n61·5% (59·4–63·5)\n\n\n\nRespiratory and intrathoracic organs (C30–C33 and C35–C39)\n161\n359\n7376\n5840\n64·5% (59·9–68·9)\n123\n359\n3304\n5840\n39·4% (32·0–46·6)\n\n\n\nBone, mesothelial, and soft tissue (C40–C41 and C45–C49)\n283\n637\n14 976\n13 091\n61·2% (57·5–64·7)\n185\n637\n6203\n13 091\n38·7% (32·2–44·9)\n\n\n\nBreast (C50)\n3774\n4877\n147 465\n70 606\n62·9% (62·2–63·7)\n2568\n4877\n66 651\n70 606\n44·2% (42·8–45·6)\n\n\n\nFemale gynaecological (C51–C58)\n1095\n2067\n52 094\n33 122\n66·3% (64·7–67·9)\n709\n2067\n23 001\n33 122\n50·6% (48·0–53·2)\n\n\n\nMale urological (C60, C62, and C63)\n234\n428\n5328\n4759\n51·2% (46·5–55·8)\n133\n428\n2294\n4759\n35·5% (28·2–42·6)\n\n\n\nProstate (C61)\n3093\n3867\n108 522\n39 592\n70·8% (70·1–71·5)\n2178\n3867\n50 373\n39 592\n55·7% (54·3–57·2)\n\n\n\nUrinary tract (C64–C68)\n1372\n2223\n70 547\n34 539\n69·8% (68·6–71·0)\n968\n2223\n31 654\n34 539\n52·5% (50·4–54·6)\n\n\n\nCNS (C69–C72)\n186\n789\n8127\n11 991\n65·2% (61·6–69·0)\n117\n789\n3506\n11 991\n49·3% (41·9–56·0)\n\n\n\nEndocrine glands (C73–C75)\n251\n490\n7543\n5870\n60·1% (56·2–64·0)\n152\n490\n3230\n5870\n43·6% (41·9–56·0)\n\n\n\nLymphoma (C81–C85)\n1806\n2427\n37 107\n27 855\n44·1% (42·5–45·8)\n1277\n2427\n16 811\n27 855\n12·8% (10·4–15·3)\n\n\n\nMyeloma (C90)\n472\n918\n29 545\n12 921\n77·5% (75·8–79·2)\n345\n918\n13 458\n12 921\n63·9% (60·7–67·0)\n\n\n\nLeukaemia (C91–C95)\n809\n1954\n24 555\n32 581\n45·1% (42·5–47·6)\n554\n1954\n11 333\n32 581\n18·5% (13·9–23·0)\n\n\n\nOther\n135\n147\n3172\n1781\nNA\n92\n147\n1524\n1781\nNA\n\n\n\nOpen in a new tab\nNA=not applicable.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nHeatmap showing overall vaccine effectiveness after the second dose and the interaction of patient age, sex, and cancer diagnosis\nGrey boxes denote insufficient data; white boxes denote inapplicable sections.Cancer subtype analysis identified that vaccine effectiveness (overall and at 3–6 months) was lower among patients with haematological malignancies than among those with solid organ malignancies, driven principally by those with a diagnosis of lymphoma or leukaemia (table 2; figure 2; appendix p 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "To examine clinically relevant covariates that might drive these differences in the cancer cohort, a multivariable logistic regression model was fitted to adjust for the effects of the age, sex, Index of Multiple Deprivation, and ethnicity (figure 3\n; appendix p 7).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Regression models were fitted for the clinically relevant covariates of age, sex, Index of Multiple Deprivation, and ethnicity.In the adjusted multivariable logistic regression, patients with stage 4 cancers versus all other stages and those aged 70 years or older versus those younger than 70 years had reduced frequencies of breakthrough infections and higher vaccine effectiveness (Figure 2, Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The greatest levels of waning vaccine effectiveness were observed in those with a diagnosis of lymphoma or leukaemia, in those who were diagnosed within 12 months of data cutoff, and in those who had received systemic anticancer treatments or radiotherapy (figure 4\n; appendix p 5).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Waning vaccine effectiveness in the cancer cohort reached its lowest point at 24–32 weeks following administration of the second vaccine dose (figure 1\n; appendix p 6).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "To ascertain whether predefined subgroups within the cancer cohort showed greater differences in vaccine effectiveness against breakthrough infections, exploratory analyses were done (table 2\n; figure 2\n; appendix p 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Cancer subtype analysis identified that vaccine effectiveness (overall and at 3–6 months) was lower among patients with haematological malignancies than among those with solid organ malignancies, driven principally by those with a diagnosis of lymphoma or leukaemia (table 2; figure 2; appendix p 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "To examine clinically relevant covariates that might drive these differences in the cancer cohort, a multivariable logistic regression model was fitted to adjust for the effects of the age, sex, Index of Multiple Deprivation, and ethnicity (figure 3\n; appendix p 7).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In the adjusted multivariable logistic regression, patients with stage 4 cancers versus all other stages and those aged 70 years or older versus those younger than 70 years had reduced frequencies of breakthrough infections and higher vaccine effectiveness (Figure 2, Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The greatest levels of waning vaccine effectiveness were observed in those with a diagnosis of lymphoma or leukaemia, in those who were diagnosed within 12 months of data cutoff, and in those who had received systemic anticancer treatments or radiotherapy (figure 4\n; appendix p 5).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  }
]